Strs Ohio Has $6.53 Million Stake in Repligen Co. (NASDAQ:RGEN)

Strs Ohio grew its holdings in Repligen Co. (NASDAQ:RGEN) by 7.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,300 shares of the biotechnology company’s stock after purchasing an additional 2,400 shares during the period. Strs Ohio’s holdings in Repligen were worth $6,526,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Lecap Asset Management Ltd. acquired a new position in shares of Repligen in the 4th quarter valued at about $241,000. Louisiana State Employees Retirement System acquired a new position in shares of Repligen in the 4th quarter valued at about $2,625,000. WCM Investment Management LLC increased its holdings in shares of Repligen by 4.2% in the 4th quarter. WCM Investment Management LLC now owns 129,954 shares of the biotechnology company’s stock valued at $24,087,000 after purchasing an additional 5,248 shares during the period. Cerity Partners LLC increased its holdings in shares of Repligen by 69.1% in the 4th quarter. Cerity Partners LLC now owns 2,668 shares of the biotechnology company’s stock valued at $480,000 after purchasing an additional 1,090 shares during the period. Finally, Conestoga Capital Advisors LLC increased its holdings in shares of Repligen by 0.4% in the 4th quarter. Conestoga Capital Advisors LLC now owns 709,738 shares of the biotechnology company’s stock valued at $127,611,000 after purchasing an additional 2,590 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Down 1.9 %

RGEN opened at $160.98 on Thursday. Repligen Co. has a 1-year low of $110.45 and a 1-year high of $211.13. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $8.99 billion, a price-to-earnings ratio of 223.59, a P/E/G ratio of 5.38 and a beta of 1.02. The business has a 50 day moving average of $190.84 and a 200-day moving average of $173.29.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The company had revenue of $155.74 million during the quarter, compared to analysts’ expectations of $155.38 million. During the same period in the prior year, the business earned $0.68 earnings per share. Repligen’s revenue for the quarter was down 16.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Repligen Co. will post 1.46 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Karen A. Dawes sold 1,000 shares of the firm’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the transaction, the director now directly owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Repligen news, Director Karen A. Dawes sold 1,000 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the transaction, the director now directly owns 87,367 shares in the company, valued at $16,892,409.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the transaction, the vice president now owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The disclosure for this sale can be found here. Insiders sold a total of 25,597 shares of company stock valued at $5,039,532 over the last ninety days. 1.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently commented on RGEN. JPMorgan Chase & Co. increased their price objective on Repligen from $170.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 20th. KeyCorp upped their target price on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Finally, Stifel Nicolaus upped their target price on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Repligen has an average rating of “Moderate Buy” and an average target price of $196.70.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.